aceso therapeutics
Aceso Therapeutics is a preclinical French biotech developing first-in-class inhaled antisense oligonucleotide therapies for cystic fibrosis via its proprietary PTGR platform, targeting CF patients underserved by current CFTR modulators, with lead asset ACT-101 advancing toward a 2027 CTA submission.
- Company typePrivate
- Founded2022
- HeadquartersMontpellier, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What aceso therapeutics does
Aceso Therapeutics is a preclinical-stage French biotech developing molecular therapies for cystic fibrosis (CF), headquartered in Montpellier, France and founded in 2022 by Thomas Tran (CEO), Magali Taulan-Cadars (CSO), and Prisca Boisguerin (CTO). The company originates from over a decade of academic research at Montpellier-based institutions (CNRS, INSERM, Université de Montpellier) and focuses on the approximately 20% of the 162,000+ CF patients worldwide who are underserved by existing CFTR modulators due to genotype constraints, partial efficacy, or prohibitive treatment costs exceeding $300K per patient per year.
The company's core technology is the PTGR (Post-Transcriptional Gene Restoration) platform, a proprietary system that restores gene expression by masking microRNA binding sites in the 3'UTR region of mRNA, protected by three international patent families (ASO-TBS filed 2013; Peptide WRAP filed 2018). The lead asset ACT-101 is a first-in-class inhaled antisense oligonucleotide (ASO) that stabilizes CFTR mRNA, with up to 60% CFTR functional activity restoration demonstrated in primary patient-derived bronchial epithelial (ALI) models across F508del homozygous and compound heterozygous genotypes. The pipeline extends to ACT-201 (CFTR protein stabilizer), ACT-301 (ACT-101/ACT-201 bitherapy), ACT-401 (splicing defect corrector), ACT-102 (nonsense mutation therapy), WRAP-1 (cell-penetrating peptide delivery vector), and ACT-105 (COPD anti-inflammatory). ACT-101 targets a Clinical Trial Application (CTA) submission in late 2027, with clinical development in 2028 and an efficacy endpoint targeted for 2031.
Aceso operates a pre-commercial, partnership-driven business model with no current revenue. Capital sources to date include a €500K SATT grant (2020), an ANR grant (2023), the Bpifrance i-Lab Innovation Competition award (2026), and an equity investment by technology transfer office SATT AxLR in March 2026; the company is also raising approximately €1.5M (partially secured) to complete regulatory preclinical studies. Development partners include WuXi (CMC), Aptar Pharma / Nanopharm (formulation and Orbital dry powder inhaler device), ILIFE (clinical study design), L2D (regulatory strategy), the Cystic Fibrosis Foundation, and Bpifrance. The company attends industry partnering events (BIO International Convention, ECFS conferences, Deeptech Connect) and pursues eventual monetization through licensing, co-development, or independent commercialization with major pharma partners.
aceso therapeutics firmographics
Firmographics- Name
- aceso therapeutics
- Legal name
- Aceso Therapeutics
- Website
- https://aceso-therapeutics.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Aceso Therapeutics is a preclinical French biotech developing first-in-class inhaled antisense oligonucleotide therapies for cystic fibrosis via its proprietary PTGR platform, targeting CF patients underserved by current CFTR modulators, with lead asset ACT-101 advancing toward a 2027 CTA submission.
- Ownership category
- akta.pro rank
aceso therapeutics industry classification
Industry- Product category
- Cystic Fibrosis Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)Gene Therapy for Rare/Monogenic DiseasesRNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Keywords
Where aceso therapeutics is headquartered
LocationHeadquarters
- HQ city
- Montpellier
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
aceso therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pre-revenue / Development Stage: Aceso Therapeutics is a pre-commercial biotech company in preclinical development stage. No revenue currently generated. The company is funded through grants, investor capital, and partnership contributions to advance ACT-101 and pipeline programs toward clinical development and eventual commercialization through licensing, co-development, or independent commercialization.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
aceso therapeutics product offering
Product offeringCore offering
Aceso Therapeutics is a preclinical-stage biotech company developing molecular therapies for cystic fibrosis (CF) and respiratory conditions. Its proprietary PTGR (Post-Transcriptional Gene Restoration) platform produces first-in-class antisense oligonucleotide (ASO) and peptide therapeutics, with lead candidate ACT-101 being an inhaled ASO that stabilizes CFTR mRNA to increase CFTR protein production in CF patients with Class II mutations. The company pursues partnerships with pharmaceutical developers, CROs, and academic institutions to advance candidates toward CTA submission targeted for 2027.
Product overview
Aceso Therapeutics is a biotech company operating a unified therapeutic platform called PTGR (Post-Transcriptional Gene Restoration) focused on cystic fibrosis. The core product is ACT-101, a first-in-class inhaled antisense oligonucleotide (ASO) that stabilizes CFTR mRNA. Supporting programs include ACT-201 (CFTR protein stabilizer), ACT-301 (bitherapy combining ACT-101 and ACT-201), ACT-401 (splicing defect corrector), ACT-102 (nonsense mutation therapy), WRAP-1 (cell-penetrating peptide delivery vector), and ACT-105 (COPD program). The pipeline addresses multiple CFTR mutation classes and disease indications, with ACT-101 as the most clinically advanced lead candidate targeting CTA submission in 2027.
Differentiator
Problem solved
Functional benefit
Products and services
- ACT-101 First-in-class inhaled antisense oligonucleotide (ASO) designed for cystic fibrosis patients with Class II (F508del) mutations. ACT-101 stabilizes CFTR mRNA to increase CFTR protein production, offered as a potential standalone or combination therapy with existing CFTR modulators. Demonstrated up to 60% CFTR functional activity restoration in patient-derived bronchial epithelial models.
- ACT-201 CFTR protein stabilization therapeutic program using a novel peptide to increase stability and half-life of mutated CFTR protein at the apical membrane. Targets cystic fibrosis patients with Class II (F508del) mutations.
- ACT-301 Bitherapy combining ACT-101 and ACT-201 for synergistic CFTR rescue, restoring both CFTR expression and protein stability for improved efficacy in cystic fibrosis patients with Class II mutations.
- ACT-401 RNA splicing defect therapeutic program targeting CF Class I mutations, designed to correct splicing defects in CFTR pre-mRNA.
- ACT-102 Nonsense mutation therapeutic program targeting CF Class I mutations, designed to address nonsense mutations in the CFTR gene.
- ACT-105 Anti-inflammatory therapeutic program targeting COPD (Chronic Obstructive Pulmonary Disease), focused on addressing inflammatory mechanisms associated with CFTR-related pathways.
Quantifiable outcome
- 60% CFTR functional activity restoration in patient-derived bronchial epithelial models
- +3 more outcomes
Companies that use aceso therapeutics
Customer profileSegments2 records
Ideal customer profiles3 records
aceso therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
aceso therapeutics partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and supporting.
- Aptar Pharma (Nanopharm)coreCollaboration to advance ACT-101, an inhaled antisense oligonucleotide for cystic fibrosis. Aptar's Nanopharm business leads formulation development and device assessment to support the candidate's clinical advancement. Follows earlier partnership between Aptar and Aceso. Partnership leverages Aptar's Orbital dry powder inhaler technology and inhalation services expertise.
- Université de Montpellier / PhyMedExpcoreResearch collaboration since December 2025 with Université de Montpellier and PhyMedExp laboratories for development of new therapeutic approaches for cystic fibrosis. PhyMedExp focuses on cardiovascular, muscle, and respiratory research from basic science to clinical applications. Collaboration includes INSERM and CNRS expertise.
- WuXimajorCollaboration with WuXi to accelerate and secure ACT-101's CMC (Chemistry, Manufacturing and Controls) development. Leverages WuXi's recognized global expertise and comprehensive capabilities in pharmaceutical development.
- ILIFEmajorCollaboration with ILIFE to anticipate the design of ACT-101's clinical study synopsis and secure next development stage by leveraging recognized clinical expertise of ILIFE's team.
- L2DmajorCollaboration with L2D to advance ACT-101's regulatory development efficiently and securely, supported by recognized regulatory expertise.
- INSERMsupportingFrench national institute for health and medical research. Key research partner with joint units including PhyMedExp for CFTR biology research.
- CNRSsupportingFrench National Centre for Scientific Research. Key academic research partner in CFTR biology and therapeutic development with joint laboratory affiliations.
- Université de LillesupportingAcademic partner in CF research collaboration contributing to the scientific foundation of the platform.
- CHU LillesupportingUniversity Hospital of Lille - clinical collaboration partner in cystic fibrosis research.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
aceso therapeutics competitors and assessment
Company assessmentDirect peers
- ProQR Therapeutics: Dutch RNA therapeutics company developing antisense oligonucleotides (e.g., eluforsen) for cystic fibrosis and other rare genetic diseases; directly comparable in modality (ASOs), indication space (CF), and patient population (CFTR mutation classes underserved by modulators).
- SpliSense: Israeli biotech developing inhaled antisense oligonucleotides for cystic fibrosis, targeting splicing defects in CFTR — extremely close comparator in technology platform (inhaled ASO), indication (CF), and clinical positioning (mutation-class-specific).
- Wave Life Sciences: Clinical-stage RNA therapeutics company with a stereopure antisense oligonucleotide platform targeting genetic diseases; comparable in ASO modality, rare-disease focus, and platform-based discovery approach.
Broad incumbents
- Vertex Pharmaceuticals: Global leader in cystic fibrosis therapeutics with Trikafta/Kaftrio franchise; sets the standard of care and competitive benchmark for any new CF therapy addressing F508del and other mutation classes.
- Ionis Pharmaceuticals: Pioneer and established leader in antisense oligonucleotide drug discovery and development; comparable in ASO modality and rare disease focus, with broader neurology and cardiometabolic pipeline providing incumbency context.
- Alnylam Pharmaceuticals: Leading RNA therapeutics company (siRNA platform) with approved drugs and rare-disease focus; comparable as a broad incumbent RNA modality player that competes for partnership and capital in the same RNA therapeutics ecosystem.
Emerging players
- Spirovant Sciences: Emerging biotech developing gene therapies for cystic fibrosis; comparable as another modality-based entrant targeting the same underserved CF population, though using AAV gene delivery instead of ASOs.
- 4D Molecular Therapeutics: Clinical-stage genetic medicines company with a CFTR gene therapy program for cystic fibrosis; comparable as an emerging CF therapeutic developer pursuing novel mechanisms for patients underserved by existing modulators.
- Translate Bio: mRNA therapeutics developer (acquired by Sanofi) that previously advanced an inhaled mRNA program for cystic fibrosis; comparable as another RNA-modality competitor targeting pulmonary CFTR delivery in the same patient segment.
- Arcturus Therapeutics: Clinical-stage RNA medicines company developing mRNA and siRNA therapeutics with proprietary lipid nanoparticle delivery; comparable as an emerging RNA therapeutics player with pulmonary and rare disease ambitions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
aceso therapeutics social profiles
Digital presenceaceso therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
aceso therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
aceso therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
aceso therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about aceso therapeutics
What does aceso therapeutics do?
Aceso Therapeutics is a preclinical-stage biotech company developing molecular therapies for cystic fibrosis (CF) and respiratory conditions. Its proprietary PTGR (Post-Transcriptional Gene Restoration) platform produces first-in-class antisense oligonucleotide (ASO) and peptide therapeutics, with lead candidate ACT-101 being an inhaled ASO that stabilizes CFTR mRNA to increase CFTR protein production in CF patients with Class II mutations. The company pursues partnerships with pharmaceutical developers, CROs, and academic institutions to advance candidates toward CTA submission targeted for 2027.
Is aceso therapeutics a public or private company?
aceso therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was aceso therapeutics founded?
aceso therapeutics was founded in 2022. It employs 1 to 10 people.
Where is aceso therapeutics based?
aceso therapeutics is headquartered in Montpellier, France, in the Europe region.
How does aceso therapeutics make money?
One revenue line is on record: pre-revenue / Development Stage.
Who are aceso therapeutics's main competitors?
Direct peers on record are ProQR Therapeutics, SpliSense and Wave Life Sciences. Broad incumbents are Vertex Pharmaceuticals, Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Emerging players are Spirovant Sciences, 4D Molecular Therapeutics, Translate Bio and Arcturus Therapeutics.
Does aceso therapeutics have an API?
No public API is recorded for aceso therapeutics.
What industry is aceso therapeutics in?
aceso therapeutics's product category is Cystic Fibrosis Therapeutics. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.